Drug Profile
Research programme: C1 inhibitors - Johnson & Johnson Pharmaceutical Research and Development
Alternative Names: C1 inhibitors research programme - 3-Dimensional Pharmaceuticals; Complement C1 esterase inhibitors research programme - 3-Dimensional PharmaceuticalsLatest Information Update: 14 Jul 2006
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Small molecules
- Mechanism of Action Complement C1s inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lupus vulgaris; Psoriasis; Reperfusion injury; Rheumatoid arthritis
Most Recent Events
- 14 Jul 2006 No development reported - Preclinical for Lupus in USA (IV)
- 14 Jul 2006 No development reported - Preclinical for Psoriasis in USA (IV)
- 14 Jul 2006 No development reported - Preclinical for Reperfusion injury in USA (IV)